Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. - Wikidata - awgldk - TriplyDB

Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice.

Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice.

http://www.wikidata.org/entity/Q34102829

about

Mouse models of frontotemporal dementia Prion-like properties of Tau protein: the importance of extracellular Tau as a therapeutic target Tau-targeted treatment strategies in Alzheimer's disease Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models Tau Biology and Tau-Directed Therapies for Alzheimer's Disease The Role of MAPT in Neurodegenerative Diseases: Genetics, Mechanisms and Therapy Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice Propagation of tau pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies.Roles of tau protein in health and disease.Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency Motor and cognitive deficits in aged tau knockout mice in two background strains.Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis.Antibody-derived in vivo imaging of tau pathology.Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy Tau aggregation and its interplay with amyloid-β.The role of telomerase protein TERT in Alzheimer's disease and in tau-related pathology in vitro.Profiling murine tau with 0N, 1N and 2N isoform-specific antibodies in brain and peripheral organs reveals distinct subcellular localization, with the 1N isoform being enriched in the nucleus.Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice.p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice.Doubly Phosphorylated Peptide Vaccines to Protect Transgenic P301S Mice against Alzheimer's Disease Like Tau Aggregation.Stabilization of Microtubule-Unbound Tau via Tau Phosphorylation at Ser262/356 by Par-1/MARK Contributes to Augmentation of AD-Related Phosphorylation and Aβ42-Induced Tau Toxicity.Trans-cellular propagation of Tau aggregation by fibrillar species Alzheimer's disease models and functional genomics-How many needles are there in the haystack?A fresh perspective from immunologists and vaccine researchers: active vaccination strategies to prevent and reverse Alzheimer's disease.Soluble forms of tau are toxic in Alzheimer's disease.Tau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimer's Disease and Other Tauopathies.Prion-like propagation of protein aggregation and related therapeutic strategies.Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology Antibody uptake into neurons occurs primarily via clathrin-dependent Fcγ receptor endocytosis and is a prerequisite for acute tau protein clearance.Evidence of Tau Hyperphosphorylation and Dystrophic Microglia in the Common Marmoset.Therapeutic strategies for tau mediated neurodegeneration.Tau passive immunization inhibits not only tau but also Aβ pathology Soluble pathological tau in the entorhinal cortex leads to presynaptic deficits in an early Alzheimer's disease model.Accelerated aging exacerbates a pre-existing pathology in a tau transgenic mouse model.Developing therapeutic antibodies for neurodegenerative disease."Prion-like" templated misfolding in tauopathies.Neurotoxic saboteurs: straws that break the hippo's (hippocampus) back drive cognitive impairment and Alzheimer's Disease.Novel disease-modifying therapeutics for the treatment of Alzheimer's disease.Tau immunotherapy and imaging.Propagation of tau pathology in Alzheimer's disease: identification of novel therapeutic targets.

P2860

Q26829009-6653BC6E-821D-4A1C-835B-49D88739BB49 Q27021159-E7D06FAC-6851-404B-B7E3-46E9DF2FA79B Q27023429-EBCAEEFA-A6A3-4B00-9A8E-A1DE68587275 Q27308146-CBDAE54D-E3B0-4EBD-AE87-C175E61BF4DE Q28071398-F27A47F8-6CBA-4200-9181-F6AD9342F818 Q28119005-E07479C1-BD82-49F7-A642-951EC435F40F Q28487708-DC475DBB-4F36-46CF-85FE-47BC5DBEC27F Q31024674-F7CBC386-3A2E-4906-AF2F-E4A095D49C73 Q33559303-90354948-EB55-4DAF-9DCC-46B1DA5F0C25 Q33640390-ADF064AB-E911-4C04-A8DF-A319F2D4FC64 Q34077327-F0E8E0FF-4443-4F0B-9613-EA1A6924B4A5 Q34205027-65348CD2-9052-4452-82D4-B309083DEC08 Q34664345-51678E3A-FB00-48DB-A5B8-44507F902AD7 Q34973787-4535F38C-44F7-4DFB-87BA-E419163343C2 Q35008256-A59317C3-3C9D-4F3E-B46B-1A215472AD82 Q35020283-17FF0778-FDE0-45F7-9A7A-A0011659715B Q35081058-D566907D-D84B-4336-8F6D-0D94E494B889 Q35204878-632459FB-7867-4859-9C81-06D4ACC928A7 Q35624263-5CFE431E-D048-43BF-9F32-1B8DE5FA5C69 Q35826638-BBEE24C6-43F4-4F05-8661-368CD9CCB63F Q35972860-C4D85885-99FB-4BB7-92C2-DFCB233726BD Q36003836-AB70ACA9-AB3D-4409-BC26-62D53826F5DF Q36193841-2D3B8779-763B-4158-98B4-438510B28B1C Q36240389-DDE71653-31F5-44A4-9BB8-6E301004D13C Q36286360-ECDE6576-1AE1-4DA3-A653-A057255D1515 Q36558485-D52C6360-AF77-4940-A3DB-A0B2F5B166E0 Q36983208-BF458F57-4064-4208-B14D-E387F52F0D2D Q37311364-7249799E-FD92-43CD-A75C-F3122A587071 Q37368709-8EDC0083-C2E7-42F9-B0FE-ADCEB3FE1E1B Q37525481-C5247BE4-DB36-48B1-A3FE-CFF3FFCB7A8D Q37550818-167F29B7-0FFA-47DA-A506-1B61261202E9 Q37579019-A8B6A5C1-0167-4593-ABFC-EF49A43C98B6 Q37625439-BF11C59F-0B23-4CBF-BA15-81D1F2BF0558 Q37678181-1DFC454A-D900-4282-89D5-3BD80F6CD1A9 Q38095360-4DD6BFBA-D5E2-4369-8B2E-D36AFF24C4C8 Q38099071-7598D88D-69BB-446F-B626-238357297CA7 Q38118901-C01EE942-1FE1-4E3E-BE4C-2B8D81C96644 Q38127470-54AD887A-C94C-428F-8B07-6B5F3D3B59E5 Q38136880-A6A873EA-E384-455D-B1B4-C13B389BA68E Q38154973-7DEFE7A0-F9E4-4DDB-A14D-2A8CF7167579

P2860

Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice.

http://www.wikidata.org/entity/Q34102829

description

2011 nî lūn-bûn

@nan

2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Tau-targeted immunization impe ...... ged P301L tau transgenic mice.

@ast

Tau-targeted immunization impe ...... ged P301L tau transgenic mice.

@en

Tau-targeted immunization impe ...... ged P301L tau transgenic mice.

@nl

type

label

Tau-targeted immunization impe ...... ged P301L tau transgenic mice.

@ast

Tau-targeted immunization impe ...... ged P301L tau transgenic mice.

@en

Tau-targeted immunization impe ...... ged P301L tau transgenic mice.

@nl

prefLabel

Tau-targeted immunization impe ...... ged P301L tau transgenic mice.

@ast

Tau-targeted immunization impe ...... ged P301L tau transgenic mice.

@en

Tau-targeted immunization impe ...... ged P301L tau transgenic mice.

@nl

P1433

Q34102829-78137D04-FB33-4E42-BE61-4E8C6BDCD51C

P1476

Q34102829-C72CFA4E-85E7-4A96-A1F8-0845C5438562

P2093

Q34102829-0AC59ED8-2029-437C-8B4A-8E2D743DCC5E

P2860

Q34102829-012DEFD9-CA18-4C70-BB2F-7AC7C63EB5C4

Q34102829-04C0A543-71EA-459E-840B-DDD4B7F881F9

Q34102829-05ABFF95-34B3-47A6-BDA3-CBA7A4DCE193

Q34102829-0957D924-91E8-4AD8-A195-EE1EB583DA7A

Q34102829-0FC979CF-58F0-43A0-9B04-9AEABB4E2190

Q34102829-159FEBA9-F947-47DB-A57F-AFF90ED3D3D0

Q34102829-1E816ACB-4B5D-4EB2-B5FC-866CC01AF109

Q34102829-2A9A27C6-9D98-4835-958E-9DFAD811904F

Q34102829-601CCDDE-3496-4E3E-B850-35AD0497AF78

Q34102829-6335199A-A528-43FB-BDA7-9A40FE9DB750

P304

Q34102829-30A2E5CB-6C0B-488B-9287-88DA7F7EEC07

P31

Q34102829-C6431793-943B-4D60-BF8B-07B0A1A0020C

P356

Q34102829-1653F077-B913-4E0B-99E6-B9E5D205DD3C

P407

Q34102829-1754DCD8-E37B-4EA6-943F-D6F9EADA4650

P433

Q34102829-8F07BF99-0D95-4CFA-B7A5-7937B25EBB46

P478

Q34102829-FF10912C-758C-44C8-8266-432C9F660067

P50

Q34102829-103BA48A-2F22-47B4-BE2A-485BAD8723B4

Q34102829-3FC1D436-ECA3-4294-844A-010735C469B2

Q34102829-BE447159-8F49-47EA-A576-D27355896065

Q34102829-CB1F2158-19FA-447A-A46A-B32395FD5DFA

P577

Q34102829-0CC7B1D1-5BC2-4D2F-A705-E581833B8A7E

P5875

Q34102829-1DB2181A-E0C5-496E-9986-4C688B0F59B6

P698

Q34102829-3D34A4FF-32FE-44A0-9C41-3B43164343CF

P921

Q34102829-E4CA2E30-63FE-43D2-894F-390399C1F95B

P932

Q34102829-4CD032CB-B55A-449A-867B-A38B09A81EC3

P356

JOURNAL.PONE.0026860

P1433

P1476

Tau-targeted immunization impe ...... ged P301L tau transgenic mice.

@en

P2093

Mian Bi

http://www.w3.org/2001/XMLSchema#string

P2860

Transmission and spreading of tauopathy in transgenic mouse brain

Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models

Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17

Tau suppression in a neurodegenerative mouse model improves memory function

Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model

Tau filament formation in transgenic mice expressing P301L tau.

ALS and FTLD: two faces of TDP-43 proteinopathy.

Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration

Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models

Immunotherapy for Alzheimer's disease.

P304

e26860

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0026860

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-12-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51884693

http://www.w3.org/2001/XMLSchema#string

P698

22174735

http://www.w3.org/2001/XMLSchema#string

P921

P932

3234245

http://www.w3.org/2001/XMLSchema#string